Moderna

Moderna, based in Cambridge, Massachusetts, and listed as MRNA, is the mRNA company whose personalised cancer vaccine intismeran autogene won the first phase 3 in its class in August 2026. Intismeran is developed with Merck and was first tested with pembrolizumab after melanoma surgery in KEYNOTE-942, and the pipeline includes mRNA-4359, a shared-antigen vaccine, plus in vivo CAR and other immuno-oncology mRNA programmes. OnCo links it to melanoma, to personalised neoantigen vaccines and self-amplifying RNA, to the Koch Institute and the Frederick National Laboratory, and to ideas on vaccines given only when a blood test turns positive and on automated manufacturing at commodity cost. Cold tumours and the immunosuppressive microenvironment are the bottleneck it confronts. Intismeran autogene has its own page.